BIOCLARMA

BIOCLARMA BIOTECNOLOGY, ANALYSIS SERVICE, MOLECULAR DIAGNOSTICS A version of "Philadelphia Sensiquant" based on ddPCR is under development.

Founding Year: 2007
Employees: 4
Employees in R&D: 2
Fields of business:
Red Biotech

Keywords:
Diagnostics, Molecular, PCR, Luminex, Real-Time, Fish, Virus, Infections, Bacteria, Transplant, Oncology, Oncohematology, Bcr-Abl, Philadelphia, 9;22, Citokines, Phosphoproteins, Cmv, Ebv, Vzv, Flu, Rsv, Hsv, Clostridium, Difficile, Bordetella, Dengue, Leiden, Protrombina, Prothrombin, Mthfr, 3m, Simple

xa, Pna, Mirna, K-Ras, Kras, Egfr, Raf, Braf, Pi3k, FV Leiden, FII, direct PCR, ddPCR, cardiac valves, food analysis. Description:
Bioclarma is a company founded in 2007 that provides products and services to public and private research and diagnostic laboratories. Our reagents and equipments for molecular diagnostics are developed with the most advanced technological solutions, providing thus a complete solution for public and private laboratories that carry out activities in the field of genetics, oncology and infectious diseases. In particular, Bioclarma launched "Philadelphia Sensiquant", a high-sensitivity one-step RT PCR kit for the detection and dosing of BCR-ABL transcript in the monitoring of CML patient's minimal residual disease. Furthermore Bioclarma developed the "Smart SNP" product range, a direct RT PCR series of products focused on SNP detection intended to be used directly on whole blood, without the need of DNA exctraction. Another series of products belonging to the the "Smart SNP" product range is currently under development. The Service of Analysis that Bioclarma provides to its customers is aimed primarily at pre-clinical research centers, to which our company is able to provide an accurate and fully documented analytic report , as well as a highly qualified assistance in the data interpretation. In particular, our laboratories offer a service activity analysis based on the use of the Bioplex ® / Luminex ® platform (array system in liquid phase), which allows, through the reading of fluorescent microspheres, multiple and simultaneous analysis of tens of parameters . The opportunities Bioclarma gives to its customers is to make available the "multiplex" analysis of cytokines, chemokines, growth factors, signal transduction molecules, mutations and polymorphisms of DNA / RNA. Among our 120 customers there are major parmaceuticals and food industries, public hospitals, universities and other industrial partners. Our team also provides an analysis service using the latest molecular tools available for applications such as search and dosage of target DNA / RNA viral, bacterial, fungal or human biological samples, Detection of mutations and polymorphisms. Bioclarma offers services analysis with methods of molecular biology such as:
Digital droplet PCR (ddPCR)
Real Time PCR
q-RT PCR
Molecular Cytogenetics (FISH)
Bioclarma can either develop assays based on specific requests, providing a qualified consulting service for the validation of diagnostic systems on different platforms, in accordance with European 98/79/EC, which regulates the design and use of in vitro diagnostic instruments. Collaborations:
University of Turin
Molinette Hospital of Turin

09/03/2023
È un progetto presentato dal Fondo Edo Tempia per valutare l'impatto dell'attività fisica sulla prevenzione del tumore p...
27/11/2022

È un progetto presentato dal Fondo Edo Tempia per valutare l'impatto dell'attività fisica sulla prevenzione del tumore prostatico, e prevede l'offerta di un programma di nordic walking a 100 uomini tra i 50 e 69 anni che non fanno sport e l'analisi di PSA ed alcuni lipidi nel sangue all'inizio e al termine del programma. È in corso un contest per ottenere un finanziamento, a questo link si può votare il progetto: https://realefoundation.org/it/contest/network4people-2022/prevenzione-di-precisione-per-il-tumore-prostatico-1537.html
Dai 5 stelline al progetto; ti arriverà poi una mail per confermare il voto! Diffondi anche ai tuoi contatti. Grazieeeee!!

Il cancro della prostata (PCa) rappresenta il tumore più diffuso nella popolazione maschile italiana. Alla diagnosi si arriva partendo generalm

Indirizzo

Via Nizza 52
Turin
10126

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando BIOCLARMA pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta L'azienda

Invia un messaggio a BIOCLARMA:

Scelte rapide

Condividi